Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy
Edgewise Therapeutics Inc (NASDAQ: EWTX) released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including BMD and Duchenne muscular dystrophy (DMD).
The ARCH study is evaluating varying doses of EDG-5506 administered daily over 24 months in 12 adults with BMD.
Related: Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics.
After 12 months of treatment, EDG-5506 was well-tolerated in all participants, with no discontinuations or dose reductions due to adverse events.
Treatment with EDG-5506 led to significant decreases in key biomarkers of muscle damage, including CK and TNNI2, reduced by an average of 37% (p=0.001) and 79% (p<0.0001) from baseline, respectively.
Nine of the twelve participants showed either a functional improvement (n=6) or exhibited stable disease (n=3) on North Star Ambulatory Assessment (NSAA) relative to their baselines after 12 months of EDG-5506 dosing.
The positive results from the 12-month ARCH study support the hypothesis that EDG-5506 administration reduces contraction-induced muscle damage in muscular dystrophies and has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies.
Based on the ARCH study, a pivotal cohort, GRAND CANYON, has been added to the CANYON study and is anticipated to begin enrollment in Q3 of 2023.
Price Action: EWTX shares closed at $6.86 on Monday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
